Eiger Mountains
Keyword Search
 
2019 | 2018 | 2017 | 2016
DateTitle 
02/06/19Eiger BioPharmaceuticals Announces Patent Protection for Lonafarnib Boosted with Ritonavir for Treatment of Hepatitis Delta Virus Infection in Europe and Japan
Expanded Patent Portfolio Now Includes U.S., Europe and Japan PALO ALTO, Calif., Feb. 6, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, announced today that the European Patent Office and the Japan Patent Office have both issued decisions to grant patents with claims covering a broad range of lonafarnib boosted with ritonavir dosing regimens for the treatment of hepa... 
Printer Friendly Version
02/04/19Eiger BioPharmaceuticals Announces Oral Presentation of Phase 2 PREVENT Study of Avexitide in Post-Bariatric Hypoglycemia (PBH) at Upcoming Endocrine Society (ENDO) Meeting 2019 in New Orleans
PALO ALTO, Calif., Feb. 4, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced an oral presentation has been granted for results of the Phase 2 PREVENT study at ENDO 2019 in New Orleans on March 25, 2019.  PREVENT is a multi-center, placebo-controlled study investigating the safety and durability of effect of 28-day dosing of subcutaneous (SC) avexitide (formerly known as exe... 
Printer Friendly Version
01/07/19Eiger BioPharmaceuticals Appoints Regulatory Expert and Industry Veteran Christine Murray, MS, RAC to its Board of Directors
PALO ALTO, Calif., Jan. 7, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for rare and ultra-rare diseases, announced today the appointment of Christine Murray, MS, RAC to its Board of Directors.  Ms. Murray is a pharmaceutical industry veteran with broad regulatory experience spanning over two decades in large pharma and biotechnology companies across diverse therapeutic areas including liver disease, metabolic di... 
Printer Friendly Version